ECP versus ruxolitinib in steroid-refractory acute GVHD - a retrospective study by the EBMT transplant complications working party.

MLA

Penack, Olaf, et al. “ECP versus Ruxolitinib in Steroid-Refractory Acute GVHD - a Retrospective Study by the EBMT Transplant Complications Working Party.” Frontiers in Immunology, vol. 14, Dec. 2023, p. 1283034. EBSCOhost, https://doi.org/10.3389/fimmu.2023.1283034.

APA

Penack, O., Peczynski, C., Boreland, W., Lemaitre, J., Afanasyeva, K., Kornblit, B., Jurado, M., Martinez, C., Natale, A., Pérez-Simón, J. A., Brunello, L., Avenoso, D., Klein, S., Ozkurt, Z. N., Herrera, C., Wichert, S., Chiusolo, P., Gavriilaki, E., Basak, G. W., … Peric, Z. (2023). ECP versus ruxolitinib in steroid-refractory acute GVHD - a retrospective study by the EBMT transplant complications working party. Frontiers in Immunology, 14, 1283034. https://doi.org/10.3389/fimmu.2023.1283034

Chicago

Penack, Olaf, Christophe Peczynski, William Boreland, Jessica Lemaitre, Ksenia Afanasyeva, Brian Kornblit, Manuel Jurado, et al. 2023. “ECP versus Ruxolitinib in Steroid-Refractory Acute GVHD - a Retrospective Study by the EBMT Transplant Complications Working Party.” Frontiers in Immunology 14 (December): 1283034. doi:10.3389/fimmu.2023.1283034.